Animal behavior models of the mechanisms underlying antipsychotic atypicality

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 27, Issue 7, 2003, Pages 1071-1079

  Geyer, Mark A ^a   Ellenbroek, Bart ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

Amphetamine; Animal models; Antipsychotics; Paw test; Phencyclidine; Prepulse inhibition; Schizophrenia

Indexed keywords

4,5,7A,8,9,10,11,11A OCTAHYDRO 10 METHYL 7H INDOLO[1,7 BC][2,6]NAPHTHYRIDINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; AMISULPRIDE; AMPHETAMINE; APOMORPHINE; ATYPICAL ANTIPSYCHOTIC AGENT; BELAPERIDONE; CHLORPROMAZINE; CLOZAPINE; DESIPRAMINE; DIAZEPAM; FLUPENTIXOL; HALOPERIDOL; JL 13; KETANSERIN; MORPHINE; OLANZAPINE; PHENCYCLIDINE; PRAZOSIN; PROMETHAZINE; QUETIAPINE; REMOXIPRIDE; RISPERIDONE; SERTINDOLE; SULPIRIDE; THIORIDAZINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIPRASIDONE; ZOTEPINE;

ANIMAL BEHAVIOR; AUDITORY STIMULATION; AVOIDANCE BEHAVIOR; CATALEPSY; CLIMBING; COGNITION; COGNITIVE DEFECT; DISEASE MODEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DYSTONIA; EXPERIMENTAL MODEL; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERACTIVITY; LATENT INHIBITION; LEARNING; LOCOMOTION; LOW DRUG DOSE; MEMORY; MONKEY; NEGATIVE SYNDROME; NONHUMAN; POSITIVE SYNDROME; PREPULSE INHIBITION; PSYCHOSOCIAL WITHDRAWAL; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SOCIAL ISOLATION; STARTLE REFLEX;

EID: 0345690103     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2003.09.003     Document Type: Article

References (95)

1. Adler L.E., Pachtman E., Franks R.D., Pecevich M., Waldo M.C., Freedman R. Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia. Biol. Psychiatry. 17:1982;639-654.
2. Adler L.E., Rose G.M., Freedman R. Neurophysiological studies of sensory gating in rats: effects of amphetamine, phencyclidine and haloperidol. Biol. Psychiatry. 21:1986;787-798.
3. Arnt J. Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol. Toxicol. 51:1982;321-329.
4. Arnt J. Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of d-amphetamine. Eur. J. Pharmacol. 283:1995;55-62.
5. Bakshi V.P., Geyer M.A. Phencyclidine-induced deficits in prepulse inhibition of startle are blocked by prazosin, an alpha1 noradrenergic antagonist. J. Pharmacol. Exp. Ther. 283:1997;666-674.
6. Bakshi V.P., Geyer M.A. Multiple limbic regions mediate the disruption of prepulse inhibition produced in rats by the noncompetitive NMDA antagonist, dizocilpine. J. Neurosci. 18:1998;8394-8401.
7. Bakshi V.P., Geyer M.A. Ontogeny of isolation rearing-induced deficits in sensorimotor gating in rats. Physiol. Behav. 6:1999;385-392.
8. Bakshi V.P., Swerdlow N.R., Geyer M.A. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J. Pharmacol. Exp. Ther. 271:1994;787-794.
9. Bakshi V.P., Tricklebank M., Neijt H.C., Lehmann-Masten V., Geyer M.A. Disruption of prepulse inhibition and increases in locomotor activity by competitive N-methyl-D-aspartate receptor antagonists in rats. J. Pharmacol. Exp. Ther. 288:1999;643-652.
10. Barrett J. Anti-psychotic drug effect on the behaviour of squirrel monkeys differentially controlled by noxious stimuli. Psychopharmacology. 77:1982;1-6.
11. Baruch I., Hemsley D.R., Gray J.A. Differential performance of acute and chronic schizophrenics in a latent inhibition task. J. Nerv. Ment. Dis. 176:1988;598-606.
12. Braff D.L., Geyer M.A. Sensorimotor gating and schizophrenia: human and animal model studies. Arch. Gen. Psychiatry. 47:1990;181-188.
13. Braff D.L., Geyer M.A., Swerdlow N.R. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology. 156:2001;234-258.
14. 2A receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse - implications for psychosis. J. Neural Transm. 100:1995;225-237.
15. Casey D.E. Behavioral effects of sertindole, risperidone, clozapine and haloperidol in cebus monkeys. Psychopharmacology. 124:1996;134-140.
16. Cools A.R. Mesolimbic dopamine and its control of locomotor activity in rats: differences in pharmacology and light/dark periodicity between the olfactory tubercle and the nucleus accumbens. Psychopharmacology. 88:1986;451-459.
17. Cools A.R., Prinssen E.P., Ellenbroek B.A. The olfactory tubercle as a site of action of neuroleptics with an atypical profile in the paw test: effect of risperidone, prothipendyl, ORG 5222, sertindole and olanzapine. Psychopharmacology. 119:1995;428-439.
18. Corbett R., Hartman H., Kerman L.L., Woods A.T., Strupczweski J.T., Helsley G.C., Conway P.C., Dunn R.W. Effects of atypical antipsychotic agents on social behavior in rodents. Pharmacol. Biochem. Behav. 45:1993;9-17.
19. Dulawa S.C., Geyer M.A. Psychopharmacology of prepulse inhibition in mice. Chin. J. Physiol. 39:1996;139-146.
20. Ellenbroek B.A. The ethological analysis of monkeys in a social setting as an animal model for schizophrenia. Olivier B., Mos J., Slangen J.L. Animal models in psychopharmacology. 1991;265-284 Birkhauser, Basel.
21. Ellenbroek B.A. Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs. Pharmacol. Ther. 57:1993;1-78.
22. Ellenbroek B., Cools A.R. The paw test: an animal model for neuroleptic drugs which fulfils the criteria for pharmacological isomorphism. Life Sci. 42:1988;1205-1213.
23. Ellenbroek B.A., Cools A.R. Animal models for schizophrenia. D'Haenen H., den Boer J.A., Westenberg H., Willner P. Textbook of Biol. Psychiatry. 2002;567-580 Wiley, Chichester.
24. Ellenbroek B., Schwarz M., Sontag K.H., Jaspers R., Cools A. Muscular rigidity and delineation of a dopamine-specific neostriatal subregion: tonic EMG activity in rats. Brain Res. 345:1985;132-140.
25. Ellenbroek B.A., Peeters B.W., Honig W.M., Cools A.R. The paw test: a behavioural paradigm for differentiating between classical and atypical neuroleptic drugs. Psychopharmacology. 93:1987;343-348.
26. Ellenbroek B.A., Van-den H.J., Cools A.R. The nucleus accumbens and forelimb muscular rigidity in rats. Exp. Brain Res. 72:1988;299-304.
27. Ellenbroek B.A., Lubbers L.J., Cools A.R. Activity of "seroquel" (ICI 204,636) in animal models for atypical properties of antipsychotics: a comparison with clozapine. Neuropsychopharmacology. 15:1996;406-416.
28. Ellenbroek B.A., Knobbout D.K., Cools A.R. The role of mesolimbic and nigrostriatal dopamine in latent inhibition as measured the conditioned taste aversion paradigm. Psychopharmacology. 129:1997;112-120.
29. Ellenbroek B.A., Sams Dodd F., Cools A.R. Simulation models for schizophrenia. Ellenbroek B.A., Cools A.R. Atypical antipsychotics. 1999;121-142 Birkhauser Verlag, Basel.
30. Ellenbroek B.A., van Luijtelaar G., Frenken M., Cools A.R. Sensory gating in rats: lack of correlation between auditory evoked potential gating and prepulse inhibition. Schizophr. Bull. 25:1999;777-788.
31. Ellenbroek B.A., Liegeois J.F., Bruhwyler J., Cools A.R. Effects of JL13, a pyridobenzoxazepine with potential atypical antipsychotic activity, in animal models for schizophrenia. J. Pharmacol Exp. Ther. 298:2001;386-391.
32. Feldon J., Weiner I. From an animal model of an attentional deficit towards new insights into the pathophysiology of schizophrenia. J. Psychiatr. Res. 26:1992;345-366.
33. Geyer M.A., Moghaddam B. Animal models relevant to schizophrenia disorders. Davis K.L., Charney D., Coyle J.T., Nemeroff C. Neuropsychopharmacology: The Fifth Generation of Progress. 2002;689-701 Lippincott Williams and Wilkins, New York. (Chapter 50).
34. Geyer M.A., Swerdlow N.R., Mansbach R.S., Braff D.L. Startle response models of sensorimotor gating and habituation deficits in schizophrenia. Brain Res. Bull. 25:1990;485-498.
35. Geyer M.A., Wilkinson L.S., Humby T., Robbins T.W. Isolation rearing of rats produces a deficit in prepulse inhibition of acoustic startle similar to that in schizophrenia. Biol. Psychiatry. 34:1993;361-372.
36. Geyer M.A., Krebs-Thomson K., Varty G.B. The effects of M100907 in pharmacological and developmental animal models of prepulse inhibition deficits in schizophrenia. Neuropsychopharmacology. 21:1999;S134-S142.
37. Geyer M.A., Swerdlow N.R., Lehmann-Masten V., Teschendorf H.-J., Traut M., Gross G. Effects of LU-111995 in three models of disrupted prepulse inhibition in rats. J. Pharmacol. Exp. Ther. 290:1999;716-724.
38. Geyer M.A., Krebs-Thomson K., Braff D.L., Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology. 156:2001;117-154.
39. Gleason S.D., Shannon H.E. Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology. 129:1997;79-84.
40. Gray N.S., Pilowsky L.S., Gray J.A., Kerwin R.W. Latent inhibition in drug naive schizophrenics: relationship to duration of illness and dopamine D2 binding using SPET. Schizophr. Res. 17:1995;95-107.
41. Idanpaan-Hiekkila J., Alhave E., Olkinuora M., Plava I. Agranulocytosis during treatment with clozapine. Eur. J. Clin. Pharmacol. 11:1977;193-198.
42. Janssen P.A.J., Niemegeers C.J.E., Schellekens K.H.L. Is it possible to predict the clinical effects of neuroleptic drugs (major tranquilizers) from animal data? Part I. Neuroleptic activity spectra for rats. Arzneim.-Forsch. 15:1965;104-117.
43. Javitt D.C., Lindsley R.L. Effects of phencyclidine on prepulse inhibition of acoustic startle response in the macaque. Psychopharmacology. 156:2001;165-168.
44. Kane J.M., Honigfeld G., Singer J., Meltzer H.Y. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry. 45:1988;789-796.
45. Kehne J.H., McCloskey T.C., Taylor V.L., Black C.K., Fadayel G.M., Schmidt C.J. Effect of the serotonin releasers 3,4- methylenedioxymethamphetamine (MDMA), 4-chloroamphetamine (PCA) and fenfluramine on acoustic and tactile startle reflexes in rats. J. Pharmacol. Exp. Ther. 260:1992;78-89.
46. Keith V.A., Mansbach R.S., Geyer M.A. Failure of haloperidol to block the effects of phencyclidine and dizocilpine on prepulse inhibition of startle. Biol. Psychiatry. 30:1991;557-566.
47. Killcross A.S., Dickinson A., Robbins T.W. Amphetamine-induced disruptions of latent inhibition are reinforcer mediated: implications for animal models of schizophrenic attentional dysfunction. Psychopharmacology. 115:1994;185-195.
48. Koek W., Colpaert F.C. Inhibition of methylphenidate-induced behaviors in rats: differences among neuroleptic. J. Pharmacol. Exp. Ther. 267:1993;181-191.
49. Kumari V., Soni W., Sharma T. Normalization of information processing deficits in schizophrenia with clozapine. Am. J. Psychiatry. 156:1999;1046-1051.
50. Light G.A., Geyer M.A., Clementz B.A., Cadenhead K.S., Braff D.L. Normal P50 suppression in schizophrenic patients treated with atypical antipsychotic medications. Am. J. Psychiatry. 157:2000;767-771.
51. Linn G., Javitt D.C. Phencyclidine (PCP) induced deficits of prepulse inhibition in monkeys. NeuroReport. 12:2001;117-120.
52. Linn G.S., Negi S.S., Gerum S.V., Javitt D.C. Reversal of phencyclidine-induced prepulse inhibition deficits by clozapine in monkeys. Psychopharmacology. 169:2003;234-239.
53. Malhotra A.K., Adler C.M., Kennison S.D., Elman I., Pickar D., Breier A. Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine. Biol. Psychiatry. 42:1997;664-668.
54. Malhotra A.K., Pinals D.A., Adler C.M., Elman I., Clifton A., Pickar D., Breier A. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology. 17:1997;141-150.
55. Mansbach R.S., Geyer M.A. Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. Neuropsychopharmacology. 2:1989;299-308.
56. Mansbach R.S., Geyer M.A. Parametric determinants in pre-stimulus modification of acoustic startle: interaction with ketamine. Psychopharmacology. 105:1991;162-168.
57. Mansbach R.S., Geyer M.A., Braff D.L. Dopaminergic stimulation disrupts sensorimotor gating in the rat. Psychopharmacology. 94:1988;507-514.
58. Mansbach R.S., Braff D.L., Geyer M.A. Prepulse inhibition of the acoustic startle response is disrupted by N-ethyl-3,4- methylenedioxymethamphetamine (MDEA) in the rat. Eur. J. Pharmacol. 167:1989;49-55.
59. 2A receptor antagonism is dependent on increased serotonergic tone. J. Neural Transm. 105:1998;365-396.
60. Martinez D., Geyer M.A. Characterization of the disruptions of prepulse inhibition and habituation of startle induced by α-ethyltryptamine. Neuropsychopharmacology. 16:1997;246-255.
61. McGhie A., Chapman J. Disorders of attention and perception in early schizophrenia. Br. J. Med. Psychol. 34:1961;103-116.
62. Meltzer H.Y. Atypical antipsychotic drugs. Bloom F.E., Kupfer D. Psychopharmacology: Fourth Generation of Progress. 1995;1277-1286 Raven Press, New York.
63. Miczek K.A., Yoshimura H. Disruption of primate social behavior by d-amphetamine and cocaine: differential antagonism by antipsychotics. Psychopharmacology. 76:1982;163-171.
64. Migler B., Warana E., Maick J. Seroquel: behavioural effects in conventional and novel tests for atypical antipsychotic drugs. Psychopharmacology. 112:1993;299-307.
65. Moore N.A., Tye N.C., Axton M.S., Risius F.C. The behavioural pharmacology of olanzapine: a novel "atypical" antipsychotic agent. J.Pharmacol. Exp. Ther. 262:1992;545-551.
66. Moore N.A., Leander J.D., Benvenga M.J., Gleason S.D., Shannon H. Behavioral pharmacology of olanzapine: a novel antipsychotic drug. J. Clin. Psychiatry. 58:1997;37-44.
67. Nagamoto H.T., Adler L.E., Hea R.A., Griffith J.M., McRae K.A., Freedman R. Gating of auditory P50 in schizophrenics: unique effects of clozapine. Biol. Psychiatry. 40:1996;181-188.
68. Oranje B., van Berckel B.N., Kemmer C., van Ree J.M., Kahn R.S., Verbaten M.N. P50 suppression and prepulse inhibition of the startle reflex in humans: a correlational study. Biol. Psychiatry. 45:1999;883-890.
69. 2A antagonist MDL 100,907 on disruption of sound and light prepulse inhibition produced by 5-HT agonists in Wistar rats. Psychopharmacology. 124:1996;107-116.
70. Perry W., Geyer M.A., Braff D.L. Sensorimotor gating and thought disturbance measured in close temporal proximity in schizophrenic patients. Arch. Gen. Psychiatry. 56:1999;277-281.
71. Pietraszek M., Ossowska K. Chronic treatment with haloperidol diminishes the phencyclidine-induced sensorimotor gating deficit in rats. Naunyn-Schmiedeberg's Arch. Pharmacol. 357:1998;466-471.
72. Powell S.B., Geyer M.A. Developmental markers of psychiatric disorders as identified by sensorimotor gating. Neurotox. Res. 4:2002;489-502.
73. Protais P., Costentin J., Schwartz J.C. Climbing behavior induced by apomorphine in mice: a simple test for the study of dopamine receptors in striatum. Psychopharmacology. 50:1976;1-6.
74. Sams Dodd F. Phencyclidine-induced stereotyped behaviour and social isolation in the rat: a possible animal model of schizophrenia. Behav. Pharmacol. 7:1996;3-23.
75. Sanchez C., Arnt J., Dragstedt N., Hyttel J., Lembol H.L., Meier E., Skarsfeldt T. Neurochemical and in vivo pharmacological profile of sertindole, a limbic-sensitive neuroleptic compound. Drug Dev. Res. 22:1991;239-250.
76. Sipes T.A., Geyer M.A. Multiple serotonin receptor subtypes modulate prepulse inhibition of the startle response in rats. Neuropharmacology. 33:1994;441-448.
77. 2A receptors in the ventral pallidum. Brain Res. 761:1997;97-104.
78. Skarsfeldt T. Differential effects of antipsychotics on place navigation of rats in the Morris water maze. A comparative study between novel and reference antipsychotics. Psychopharmacology. 124:1996;126-133.
79. Stevens K.E., Fuller L.L., Rose G.M. Dopaminergic and noradrenergic modulation of amphetamine-induced changes in auditory gating. Brain Res. 555:1991;91-98.
80. Strauss J.S., Kokes R.F., Klorman R., Sacksteder J.L. Premorbid adjustment in schizophrenia: concepts, measures and implications: I. The concept of premorbid adjustment. Schizophr. Bull. 3:1977;182-185.
81. Struyker B.H., Cools A.R. (3,4-Dihydroxyphenylimino)-2-imidazoline (DPI): a stimulant of alpha-adrenoceptors and dopamine receptors. J. Pharm. Pharmacol. 36:1984;859-860.
82. Swerdlow N.R., Vaccarino F., Amalric M., Koob G. Neural substrates for the motor-activating proper ties of psychostimulants: a review of recent findings. Pharmacol. Biochem. Behav. 25:1986;233-248.
83. Swerdlow N.R., Braff D.L., Geyer M.A., Koob G.F. Central dopamine hyperactivity in rats mimics abnormal sensory gating of the acoustic startle response in schizophrenics. Biol. Psychiatry. 21:1986;23-33.
84. Swerdlow N.R., Keith V.A., Braff D.L., Geyer M.A. Effects of spiperone, raclopride, SCH 23390 and clozapine on apomorphine inhibition of sensorimotor gating of the startle response in the rat. J. Pharmacol. Exp. Ther. 256:1991;530-536.
85. Swerdlow N.R., Braff D.L., Taaid N., Geyer M.A. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch. Gen. Psychiatry. 51:1994;139-154.
86. Swerdlow N.R., Braff D.L., Hartston H., Perry W., Geyer M.A. Latent inhibition in schizophrenia. Schizophr. Res. 20:1996;91-103.
87. Swerdlow N.R., Bakshi V.P., Waikar J., Taaid N., Geyer M.A. Seroquel, clozapine and chlorpromazine restore sensorimotor gating in ketamine-treated rats. Psychopharmacology. 140:1998;75-80.
88. Swerdlow N.R., Geyer M.A., Braff D.L. Neural circuitry of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology. 156:2001;194-215.
89. Varty G.B., Geyer M.A. Effects of isolation rearing on startle reactivity, habituation, and prepulse inhibition of male Lewis, Sprague-Dawley, and Fischer F344 rats. Behav. Neurosci. 112:1998;1450-1457.
90. 2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats. Neuropsychopharmacology. 20:1999;311-321.
91. Vasse M., Protais P., Costentin J., Schwartz J.C. Unexpected potentiation by discriminant benzamide derivatives of stereotyped behaviours elicited by dopamine agonists in mice. Naunyn-Schmiedeberg's Arch. Pharmacol. 329:1985;108-116.
92. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch.Gen. Psychiatry. 44:1987;660-669.
93. Weiner I., Lubow R.E., Feldon J. Disruption of latent inhibition by acute administration of low doses of amphetamine. Pharmacol. Biochem. Behav. 30:1988;871-878.
94. Wilkinson L.S., Killcross S.S., Humby T., Hall F.S., Geyer M.A., Robbins T.W. Social isolation in the rat produces developmentally specific deficits in prepulse inhibition of the acoustic startle response without disrupting latent inhibition. Neuropsychopharmacology. 10:1994;61-72.
95. Williams J.H., Wellman N.A., Geaney D.P., Cowen P.J., Feldon J., Rawlins J.N. Reduced latent inhibition in people with schizophrenia: an effect of psychosis or its treatment. Br. J. Psychiatry. 172:1998;243-249.